Investor Presentation H1 2023

84 Investor presentation First six months of 2023 Rare disease sales decreased by 18%, impacted by NorditropinⓇ supply constraints NovoSevenⓇ and NorditropinⓇ DKK billion account for ~70% of Rare disease sales DKK billion Global Rare disease franchise 25 25 1% 4% 1% -18% 1% 4% 1% |-18% 20 20 20 15 10 5 0 2020 2021 2022 H1 2023 NovoSevenⓇ NorditropinⓇ Other haemophilia products¹ Other Rare disease Growth at CER Note: Company reported sales; CER: Constant exchange rates; 1Other haemophilia products primarily consists of Vagifem® and ActivelleⓇ 8 15 7 7 10 3 12 12 13 5 5 2020 2021 2022 H1 2023 IO NAO Growth at CER Novo NordiskⓇ

View entire presentation